Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Nov 15, 2006 (Vol. 26, No. 20)

BioPAX Home

URL:www.biopax.org
  • Ambitious
  • Not for the faint of heart
In terms of gathering pathway related information, “BioPAX” takes a collaborative approach to create a data exchange format with the same end goal. Designed as an open source project, the site has a wiki page that records development activity. Access to participation requires registration, and after this is done, visitors can participate in discussions/forums and contribute to the body of knowledge. The site’s road map identifies four levels of complexity, of which only the first and second have had any significant progress noted to date. They include small molecule pathways, interactions, and classes (level one), DNA interactions, interaction networks and classes (level two), gene interactions, pathways, and classes (level three), and more. At the far end, the project aims to capture abstract relationships between biological entities and cell-level interactors. Sound techie? It is, but who said life was simple?
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »